B.R.A.I.N in People Living With HIV Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-16

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People living with HIV (PLWH) often have memory and thinking problems, which can range from mild to severe. These problems, which are called neurocognitive impairment (NCI), can appear even when PLWH are taking medicine to manage their HIV.

PLWH who are experiencing NCI can have difficulties managing everyday activities. For instance, they might not remember to take their medicine on time, they might struggle to manage their money properly, and they might even be at a higher risk of passing HIV on to other. Ultimately, PLWH who are experiencing NCI might not enjoy life as much as others do.

Currently, there are no specific medicines designed to treat NCI in PLWH. There are, however, some useful memory and thinking strategies that can help improve cognitive abilities. These strategies are called cognitive remediation (CR).

In South Africa, there are many PLWH. Unfortunately, the country does not have clear plans for identifying and managing NCI in PLWH. It's difficult to use CR in South Africa because of cultural differences between where the strategies were developed and the patients who might need to use it, limited healthcare resources, and HIV clinics not having enough information about NCI.

There are, however, some promising ways to deal with these issues. For example, it can be helpful to involve regular counselors and to use simple tests on mobile phones to find people who need assistance. With some effort and creativity, investigators can improve the situation and help PLWH lead better lives.

The proposed study is a unique opportunity to find new ways to help PLWH and others with brain-related diseases who might be experiencing NCI. Investigators want to explore ways to use cognitive exercises to improve thinking abilities. This study will be the first of its kind because investigators will adapt these exercises to fit the cultures and languages of South Africa, where many people are affected by HIV and NCI.

By doing this research, investigators hope to make important progress in addressing NCI in HIV and similar conditions. Investigators will learn how to make these cognitive exercises work best in South Africa's public clinics, and this knowledge can help people with NCI live better lives. Our goal is to improve healthcare not only in South Africa but also in other parts of the world that might be facing similar challenges with improving the lives of PLWH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Training for the Remediation of Functional Brain Health in HIV

NCT02571504

HIV - Human Immunodeficiency Virus Cognitive Impairment

COMPLETED NA

Cognitive Training With and Without tDCS to Improve Cognition in HIV

NCT02647645

HIV Mild Neurocognitive Disorder

TERMINATED NA

Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV

NCT03440840

COMPLETED NA

Cognitive Remediation for HIV-associated Neurocognitive Dysfunction

NCT02671526

HIV-associated Neurocognitive Dysfunction

COMPLETED NA

CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy

NCT02343887

HIV

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neurocognitive Impairment (NCI) is a condition where HIV infection affects the brain, leading to problems with memory, thinking, and other cognitive functions. It is a common issue among people living with HIV, even those who are receiving antiretroviral therapy (ART) to control the virus. The exact reasons why NCI occurs in HIV are not fully understood, but it is likely influenced by several factors, including direct HIV-related processes in the central nervous system and other contributing elements like stress.

NCI can range from mild cognitive deficits to more severe impairments that impact daily functioning and quality of life. People experiencing NCI may find it challenging to remember things, concentrate, make decisions, and perform tasks they once managed easily. This condition can also affect their adherence to HIV treatment, which is crucial for managing the infection effectively.

In South Africa, where HIV prevalence is high, NCI poses a significant concern. Despite its prevalence, there are no established protocols for the routine screening and management of NCI in HIV clinics. This lack of systematic approach hinders early identification and appropriate intervention for affected individuals.

The consequences of NCI in HIV are not just medical; they extend to functional and public health aspects as well. For instance, impaired cognitive abilities can hinder a person's ability to adhere to their medication schedule, leading to treatment challenges and potential disease progression. Additionally, NCI can hinder daily activities and job performance, affecting overall productivity and livelihood. Furthermore, those with cognitive impairments may be at a higher risk of transmitting HIV to others, as they might struggle with understanding and adhering to preventive measures.

Currently, there are no specific pharmacological treatments available to directly address NCI in HIV. However, cognitive remediation (CR) strategies have shown promise in managing and improving cognitive abilities in this population. CR involves structured activities and exercises designed to enhance memory, attention, problem-solving, and other cognitive functions. While more research is needed, CR holds potential for improving the quality of life for individuals living with HIV and NCI.

Implementing CR interventions in South Africa faces several challenges. The country's cultural diversity calls for approaches that are sensitive and adaptable to different communities. Moreover, limited healthcare resources and the lack of awareness and guidelines for NCI in HIV clinics add further complexity to the situation.

One promising approach involves task-shifting strategies, which involve the participation of lay counselors in the delivery of CR interventions. This can help address resource constraints while potentially reaching more affected individuals. Additionally, utilizing mobile health screening tests can aid in identifying people with NCI, especially in remote or underserved areas.

The proposed study provides a unique opportunity to establish an entirely new therapeutic approach on the African continent for treating neurocognitive impairment (NCI) in people living with HIV (PWH) and patients with other brain-involved diseases. Additionally, it aims to explore barriers to the utility and future implementation of cognitive remediation (CR) in public clinics.

This study will be the first of its kind in several ways: (1) It will culturally and linguistically adapt a CR program specifically for HIV-associated NCI in a low- and middle-income setting with high rates of HIV and NCI; (2) It will assess the usability and acceptability of the CR intervention by both key stakeholders, such as the Department of Health, and PWH in South Africa; (3) It will combine evidence-based restorative and compensatory cognitive remediation strategies and evaluate which components are most acceptable and feasible to implement in the South African context.

By undertaking this groundbreaking research, investigators aim to make significant strides in addressing NCI in HIV and potentially extend the benefits to other brain-involved conditions. The study's outcomes will provide valuable insights into the implementation of CR in the country's public clinics and pave the way for more effective and culturally appropriate interventions for improving cognitive function in those affected by HIV-associated NCI and other related diseases. Through this collaborative effort, investigators hope to improve the lives of individuals living with NCI and contribute to the advancement of healthcare in South Africa and beyond.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-associated Neurocognitive Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Recruited participants will first be screened for eligibility and required to provide informed consent. After the baseline assessment, participants will be randomized into one of two study arms: an active experimental group receiving CR (CogSMART and BrainHQ©) or an attention-matched control group. Measures, both subjective and objective, will evaluate participants' cognition, behavior, and functional abilities. Exit focus groups will gather participant feedback. The study aims to inform a larger RCT to enhance cognitive functioning and well-being among PWH in South Africa.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Randomization to study arm. Participants will be randomized into one of two study arms after the baseline assessment: an active experimental group receiving the CR, or an attention-matched control group. Because our sample size (N=43) is smaller than 100, investigators will use block randomization to assign participant numbers equally across each arm. To prevent the executer (the neuropsychology technician) from predicting the next assignment, they will be kept ignorant of the block size. Concealing the allocation sequence from those assigning participants, will prevent selection bias. Allocation numbers will be placed in individually sealed brown envelopes by the project manager prior to study commencement.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined CogSMART and BrainHQ intervention group

Intervention: The experimental condition in this trial is a combination of CogSMART and BrainHQ. This integrated intervention helps individuals with cognitive impairment improve daily activities and achieve goals. CogSMART, a compensatory cognitive remediation (C-CR) program, employs techniques to enhance prospective memory, attention, learning/memory, and executive functioning. BrainHQ, a restorative cognitive remediation (R-CR) program, provides game-like modules targeting memory, attention, and executive functions. Together, they offer a comprehensive approach, combining C-CR with R-CR to reduce impairment and enhance problem-solving skills.

Group Type EXPERIMENTAL

Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©

Intervention Type BEHAVIORAL

The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.

Attention-matched Combined CogSMART and BrainHQ Control group

This control-matched approach to the CogSMART group, currently utilized in Dr. Twamley's studies, has been well received by participants, with no significant increase in dropout rates. Additionally, control participants will receive the BrainHQ component, involving Internet Navigation Training previously employed by Dr. Vance consisting of 20 sessions lasting 30 minutes each aimed to provide no therapeutic benefit.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©

The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 30 and 50 years;
* ≥ 8 years of schooling;
* Fluent Xhosa speaking;
* HIV-positive;
* on Antiretroviral therapy (ART);
* ability to sign informed consent;
* willing to attend: (a) two NP testing sessions, (b) a minimum of 10 hours (twenty 30-minute sessions) of R-CR sessions, and (c) 10 CogSMART sessions over a period of five weeks; and
* meeting the criteria for NCI (as described further in document).

Exclusion Criteria

* Participants with significant neuro-medical comorbidities (e.g., schizophrenia, epilepsy, bipolar disorder, multiple sclerosis, intellectual disability) necessitate exclusion. These comorbidities will be assessed for during screening.
* Other conditions (e.g., legally blind or deaf, currently undergoing radiation or chemotherapy, a history of brain trauma with a loss of consciousness greater than 30 minutes) that could impact cognitive functioning, testing or consistent study participation over 7 weeks necessitate exclusion; again, this information is conferred in the screen.

Minimum Eligible Age

30 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes